Morgan Stanley maintains Amgen at Equal-Weight, raises price target to $410 from $359

What happened

Morgan Stanley kept its Equal-Weight rating on Amgen, meaning it expects performance broadly in line with the market, and raised its price target to $410 from $359. The new target is 14.2% higher than the prior target but implies 11.1% downside from Amgen’s Nov. 3 closing price of $461.26.

Confirmed

Global impact / market context

The higher target signals Morgan Stanley sees more value than before, but its rating stayed unchanged and the target remains below the cited closing price. If investors use that estimate to guide decisions, it may temper expectations for Amgen’s share gains rather than signal a stronger endorsement.

Analyst inference

Recent analyst targets show differing views: five notes from the past 30 days span $398 to $480, while Morgan Stanley’s new $410 target sits near the lower end. The article reports other ratings, but provides no company results or broader market reaction.

Confirmed

What to watch

1. Compare future analyst targets with the reported $398–$480 range; a cluster of lower or higher revisions could indicate changing expectations for Amgen’s shares. Analyst inference
2. Watch for any change in Morgan Stanley’s Equal-Weight rating or target, since a stronger rating would be a clearer shift than this target increase alone. Analyst inference
3. Track whether Amgen’s share price moves toward or away from Morgan Stanley’s $410 target, which the article says is below the Nov. 3 close. Analyst inference

Evidence

• Original source link unavailable